降圧剤のグローバル市場展望 2023年-2029年:利尿薬、アンジオテンシン変換酵素(ACE)阻害薬、アンジオテンシン受容体遮断薬(ARB)、カルシウムチャネル遮断薬、ベータ遮断薬、アルファ遮断薬、血管拡張薬&レニン阻害薬

■ 英語タイトル:Antihypertensive Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート(データ管理コード:MMG23JU5681)■ 発行会社/調査会社:Market Monitor Global
■ 商品コード:MMG23JU5681
■ 発行日:2023年6月
■ 調査対象地域:グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野:医薬品&医療
■ ページ数:128
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後2-3営業日)
■ 販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,250 ⇒換算¥494,000見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD4,225 ⇒換算¥642,200見積依頼/購入/質問フォーム
Enterprise User(閲覧人数制限なし)USD4,875 ⇒換算¥741,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[降圧剤のグローバル市場展望 2023年-2029年:利尿薬、アンジオテンシン変換酵素(ACE)阻害薬、アンジオテンシン受容体遮断薬(ARB)、カルシウムチャネル遮断薬、ベータ遮断薬、アルファ遮断薬、血管拡張薬&レニン阻害薬]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

当調査レポートは次の情報を含め、世界の降圧剤市場規模と予測を収録しています。・世界の降圧剤市場:売上、2018年-2023年、2024年-2029年
・世界の降圧剤市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の降圧剤市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「利尿薬」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

降圧剤のグローバル主要企業は、Pfizer、 Norvatis、 Merck & Co.、 Sanofi、 AstraZeneca、 GSK、 Daiichi-Sankyo、 Boehringer-Ingelheim、 Bayer、 Johnson & Johnson、 Bristol-Myers Squibb、 Tekeda、 Ranbaxy Laboratories、 Shihuida Pharm、 Second Pharmaceutical、 Lupin Limited.、 Yangtze River Pharmaceutical、 Hengrui Medicine、 Qilu Pharmaceutical、 HUALON、 Dawnrays、 HISUN Pharmceuticalなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、降圧剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の降圧剤市場:タイプ別、2018年-2023年、2024年-2029年
世界の降圧剤市場:タイプ別市場シェア、2022年
・利尿薬、アンジオテンシン変換酵素(ACE)阻害薬、アンジオテンシン受容体遮断薬(ARB)、カルシウムチャネル遮断薬、ベータ遮断薬、アルファ遮断薬、血管拡張薬&レニン阻害薬

世界の降圧剤市場:用途別、2018年-2023年、2024年-2029年
世界の降圧剤市場:用途別市場シェア、2022年
・病院薬局、小売薬局、オンライン薬局、その他

世界の降圧剤市場:地域・国別、2018年-2023年、2024年-2029年
世界の降圧剤市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における降圧剤のグローバル売上、2018年-2023年
・主要企業における降圧剤のグローバル売上シェア、2022年
・主要企業における降圧剤のグローバル販売量、2018年-2023年
・主要企業における降圧剤のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Pfizer、 Norvatis、 Merck & Co.、 Sanofi、 AstraZeneca、 GSK、 Daiichi-Sankyo、 Boehringer-Ingelheim、 Bayer、 Johnson & Johnson、 Bristol-Myers Squibb、 Tekeda、 Ranbaxy Laboratories、 Shihuida Pharm、 Second Pharmaceutical、 Lupin Limited.、 Yangtze River Pharmaceutical、 Hengrui Medicine、 Qilu Pharmaceutical、 HUALON、 Dawnrays、 HISUN Pharmceutical

*************************************************************

・調査・分析レポートの概要
降圧剤市場の定義
市場セグメント
世界の降圧剤市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の降圧剤市場規模
世界の降圧剤市場規模:2022年 VS 2029年
世界の降圧剤市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの降圧剤の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の降圧剤製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:利尿薬、アンジオテンシン変換酵素(ACE)阻害薬、アンジオテンシン受容体遮断薬(ARB)、カルシウムチャネル遮断薬、ベータ遮断薬、アルファ遮断薬、血管拡張薬&レニン阻害薬
降圧剤のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:病院薬局、小売薬局、オンライン薬局、その他
降圧剤の用途別グローバル売上・予測

・地域別市場分析
地域別降圧剤市場規模 2022年と2029年
地域別降圧剤売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
Pfizer、 Norvatis、 Merck & Co.、 Sanofi、 AstraZeneca、 GSK、 Daiichi-Sankyo、 Boehringer-Ingelheim、 Bayer、 Johnson & Johnson、 Bristol-Myers Squibb、 Tekeda、 Ranbaxy Laboratories、 Shihuida Pharm、 Second Pharmaceutical、 Lupin Limited.、 Yangtze River Pharmaceutical、 Hengrui Medicine、 Qilu Pharmaceutical、 HUALON、 Dawnrays、 HISUN Pharmceutical
...

This report aims to provide a comprehensive presentation of the global market for Antihypertensive, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihypertensive. This report contains market size and forecasts of Antihypertensive in global, including the following market information:
Global Antihypertensive Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Antihypertensive Market Sales, 2018-2023, 2024-2029, (Units)
Global top five Antihypertensive companies in 2022 (%)
The global Antihypertensive market was valued at US$ 19810 million in 2022 and is projected to reach US$ 22820 million by 2029, at a CAGR of 2.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Increase in blood pressure is measured in terms of systolic and diastolic blood pressure exerted by blood on the wall of artery and hence it is also termed as arterial hypertension. Reduction in blood pressure minimizes the risk of heart failure, ischaemic heart diseases, dementia and mortality due to hypertension.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Antihypertensive manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Antihypertensive Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Antihypertensive Market Segment Percentages, by Type, 2022 (%)
Diuretics
Angiotensin Converting Enzyme (ACE) Inhibitors
Angiotensin Receptor Blockers (ARBs)
Calcium Channel Blockers
Beta Blockers
Alpha Blockers
Vasodilators & Renin Inhibitors
Global Antihypertensive Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Antihypertensive Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Global Antihypertensive Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Antihypertensive Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Antihypertensive revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Antihypertensive revenues share in global market, 2022 (%)
Key companies Antihypertensive sales in global market, 2018-2023 (Estimated), (Units)
Key companies Antihypertensive sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Norvatis
Merck & Co.
Sanofi
AstraZeneca
GSK
Daiichi-Sankyo
Boehringer-Ingelheim
Bayer
Johnson & Johnson
Bristol-Myers Squibb
Tekeda
Ranbaxy Laboratories
Shihuida Pharm
Second Pharmaceutical
Lupin Limited.
Yangtze River Pharmaceutical
Hengrui Medicine
Qilu Pharmaceutical
HUALON
Dawnrays
HISUN Pharmceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Antihypertensive, market overview.
Chapter 2: Global Antihypertensive market size in revenue and volume.
Chapter 3: Detailed analysis of Antihypertensive manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Antihypertensive in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Antihypertensive capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

世界の市場調査レポート販売サイト(H&Iグローバルリサーチ株式会社運営)
*** レポート目次(コンテンツ)***

1 Introduction to Research & Analysis Reports
1.1 Antihypertensive Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Antihypertensive Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Antihypertensive Overall Market Size
2.1 Global Antihypertensive Market Size: 2022 VS 2029
2.2 Global Antihypertensive Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Antihypertensive Sales: 2018-2029
3 Company Landscape
3.1 Top Antihypertensive Players in Global Market
3.2 Top Global Antihypertensive Companies Ranked by Revenue
3.3 Global Antihypertensive Revenue by Companies
3.4 Global Antihypertensive Sales by Companies
3.5 Global Antihypertensive Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Antihypertensive Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Antihypertensive Product Type
3.8 Tier 1, Tier 2 and Tier 3 Antihypertensive Players in Global Market
3.8.1 List of Global Tier 1 Antihypertensive Companies
3.8.2 List of Global Tier 2 and Tier 3 Antihypertensive Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Antihypertensive Market Size Markets, 2022 & 2029
4.1.2 Diuretics
4.1.3 Angiotensin Converting Enzyme (ACE) Inhibitors
4.1.4 Angiotensin Receptor Blockers (ARBs)
4.1.5 Calcium Channel Blockers
4.1.6 Beta Blockers
4.1.7 Alpha Blockers
4.1.8 Vasodilators & Renin Inhibitors
4.2 By Type – Global Antihypertensive Revenue & Forecasts
4.2.1 By Type – Global Antihypertensive Revenue, 2018-2023
4.2.2 By Type – Global Antihypertensive Revenue, 2024-2029
4.2.3 By Type – Global Antihypertensive Revenue Market Share, 2018-2029
4.3 By Type – Global Antihypertensive Sales & Forecasts
4.3.1 By Type – Global Antihypertensive Sales, 2018-2023
4.3.2 By Type – Global Antihypertensive Sales, 2024-2029
4.3.3 By Type – Global Antihypertensive Sales Market Share, 2018-2029
4.4 By Type – Global Antihypertensive Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Antihypertensive Market Size, 2022 & 2029
5.1.2 Hospital Pharmacy
5.1.3 Retail Pharmacy
5.1.4 Online Pharmacy
5.1.5 Others
5.2 By Application – Global Antihypertensive Revenue & Forecasts
5.2.1 By Application – Global Antihypertensive Revenue, 2018-2023
5.2.2 By Application – Global Antihypertensive Revenue, 2024-2029
5.2.3 By Application – Global Antihypertensive Revenue Market Share, 2018-2029
5.3 By Application – Global Antihypertensive Sales & Forecasts
5.3.1 By Application – Global Antihypertensive Sales, 2018-2023
5.3.2 By Application – Global Antihypertensive Sales, 2024-2029
5.3.3 By Application – Global Antihypertensive Sales Market Share, 2018-2029
5.4 By Application – Global Antihypertensive Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Antihypertensive Market Size, 2022 & 2029
6.2 By Region – Global Antihypertensive Revenue & Forecasts
6.2.1 By Region – Global Antihypertensive Revenue, 2018-2023
6.2.2 By Region – Global Antihypertensive Revenue, 2024-2029
6.2.3 By Region – Global Antihypertensive Revenue Market Share, 2018-2029
6.3 By Region – Global Antihypertensive Sales & Forecasts
6.3.1 By Region – Global Antihypertensive Sales, 2018-2023
6.3.2 By Region – Global Antihypertensive Sales, 2024-2029
6.3.3 By Region – Global Antihypertensive Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Antihypertensive Revenue, 2018-2029
6.4.2 By Country – North America Antihypertensive Sales, 2018-2029
6.4.3 US Antihypertensive Market Size, 2018-2029
6.4.4 Canada Antihypertensive Market Size, 2018-2029
6.4.5 Mexico Antihypertensive Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Antihypertensive Revenue, 2018-2029
6.5.2 By Country – Europe Antihypertensive Sales, 2018-2029
6.5.3 Germany Antihypertensive Market Size, 2018-2029
6.5.4 France Antihypertensive Market Size, 2018-2029
6.5.5 U.K. Antihypertensive Market Size, 2018-2029
6.5.6 Italy Antihypertensive Market Size, 2018-2029
6.5.7 Russia Antihypertensive Market Size, 2018-2029
6.5.8 Nordic Countries Antihypertensive Market Size, 2018-2029
6.5.9 Benelux Antihypertensive Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Antihypertensive Revenue, 2018-2029
6.6.2 By Region – Asia Antihypertensive Sales, 2018-2029
6.6.3 China Antihypertensive Market Size, 2018-2029
6.6.4 Japan Antihypertensive Market Size, 2018-2029
6.6.5 South Korea Antihypertensive Market Size, 2018-2029
6.6.6 Southeast Asia Antihypertensive Market Size, 2018-2029
6.6.7 India Antihypertensive Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Antihypertensive Revenue, 2018-2029
6.7.2 By Country – South America Antihypertensive Sales, 2018-2029
6.7.3 Brazil Antihypertensive Market Size, 2018-2029
6.7.4 Argentina Antihypertensive Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Antihypertensive Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Antihypertensive Sales, 2018-2029
6.8.3 Turkey Antihypertensive Market Size, 2018-2029
6.8.4 Israel Antihypertensive Market Size, 2018-2029
6.8.5 Saudi Arabia Antihypertensive Market Size, 2018-2029
6.8.6 UAE Antihypertensive Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Antihypertensive Major Product Offerings
7.1.4 Pfizer Antihypertensive Sales and Revenue in Global (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Norvatis
7.2.1 Norvatis Company Summary
7.2.2 Norvatis Business Overview
7.2.3 Norvatis Antihypertensive Major Product Offerings
7.2.4 Norvatis Antihypertensive Sales and Revenue in Global (2018-2023)
7.2.5 Norvatis Key News & Latest Developments
7.3 Merck & Co.
7.3.1 Merck & Co. Company Summary
7.3.2 Merck & Co. Business Overview
7.3.3 Merck & Co. Antihypertensive Major Product Offerings
7.3.4 Merck & Co. Antihypertensive Sales and Revenue in Global (2018-2023)
7.3.5 Merck & Co. Key News & Latest Developments
7.4 Sanofi
7.4.1 Sanofi Company Summary
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Antihypertensive Major Product Offerings
7.4.4 Sanofi Antihypertensive Sales and Revenue in Global (2018-2023)
7.4.5 Sanofi Key News & Latest Developments
7.5 AstraZeneca
7.5.1 AstraZeneca Company Summary
7.5.2 AstraZeneca Business Overview
7.5.3 AstraZeneca Antihypertensive Major Product Offerings
7.5.4 AstraZeneca Antihypertensive Sales and Revenue in Global (2018-2023)
7.5.5 AstraZeneca Key News & Latest Developments
7.6 GSK
7.6.1 GSK Company Summary
7.6.2 GSK Business Overview
7.6.3 GSK Antihypertensive Major Product Offerings
7.6.4 GSK Antihypertensive Sales and Revenue in Global (2018-2023)
7.6.5 GSK Key News & Latest Developments
7.7 Daiichi-Sankyo
7.7.1 Daiichi-Sankyo Company Summary
7.7.2 Daiichi-Sankyo Business Overview
7.7.3 Daiichi-Sankyo Antihypertensive Major Product Offerings
7.7.4 Daiichi-Sankyo Antihypertensive Sales and Revenue in Global (2018-2023)
7.7.5 Daiichi-Sankyo Key News & Latest Developments
7.8 Boehringer-Ingelheim
7.8.1 Boehringer-Ingelheim Company Summary
7.8.2 Boehringer-Ingelheim Business Overview
7.8.3 Boehringer-Ingelheim Antihypertensive Major Product Offerings
7.8.4 Boehringer-Ingelheim Antihypertensive Sales and Revenue in Global (2018-2023)
7.8.5 Boehringer-Ingelheim Key News & Latest Developments
7.9 Bayer
7.9.1 Bayer Company Summary
7.9.2 Bayer Business Overview
7.9.3 Bayer Antihypertensive Major Product Offerings
7.9.4 Bayer Antihypertensive Sales and Revenue in Global (2018-2023)
7.9.5 Bayer Key News & Latest Developments
7.10 Johnson & Johnson
7.10.1 Johnson & Johnson Company Summary
7.10.2 Johnson & Johnson Business Overview
7.10.3 Johnson & Johnson Antihypertensive Major Product Offerings
7.10.4 Johnson & Johnson Antihypertensive Sales and Revenue in Global (2018-2023)
7.10.5 Johnson & Johnson Key News & Latest Developments
7.11 Bristol-Myers Squibb
7.11.1 Bristol-Myers Squibb Company Summary
7.11.2 Bristol-Myers Squibb Antihypertensive Business Overview
7.11.3 Bristol-Myers Squibb Antihypertensive Major Product Offerings
7.11.4 Bristol-Myers Squibb Antihypertensive Sales and Revenue in Global (2018-2023)
7.11.5 Bristol-Myers Squibb Key News & Latest Developments
7.12 Tekeda
7.12.1 Tekeda Company Summary
7.12.2 Tekeda Antihypertensive Business Overview
7.12.3 Tekeda Antihypertensive Major Product Offerings
7.12.4 Tekeda Antihypertensive Sales and Revenue in Global (2018-2023)
7.12.5 Tekeda Key News & Latest Developments
7.13 Ranbaxy Laboratories
7.13.1 Ranbaxy Laboratories Company Summary
7.13.2 Ranbaxy Laboratories Antihypertensive Business Overview
7.13.3 Ranbaxy Laboratories Antihypertensive Major Product Offerings
7.13.4 Ranbaxy Laboratories Antihypertensive Sales and Revenue in Global (2018-2023)
7.13.5 Ranbaxy Laboratories Key News & Latest Developments
7.14 Shihuida Pharm
7.14.1 Shihuida Pharm Company Summary
7.14.2 Shihuida Pharm Business Overview
7.14.3 Shihuida Pharm Antihypertensive Major Product Offerings
7.14.4 Shihuida Pharm Antihypertensive Sales and Revenue in Global (2018-2023)
7.14.5 Shihuida Pharm Key News & Latest Developments
7.15 Second Pharmaceutical
7.15.1 Second Pharmaceutical Company Summary
7.15.2 Second Pharmaceutical Business Overview
7.15.3 Second Pharmaceutical Antihypertensive Major Product Offerings
7.15.4 Second Pharmaceutical Antihypertensive Sales and Revenue in Global (2018-2023)
7.15.5 Second Pharmaceutical Key News & Latest Developments
7.16 Lupin Limited.
7.16.1 Lupin Limited. Company Summary
7.16.2 Lupin Limited. Business Overview
7.16.3 Lupin Limited. Antihypertensive Major Product Offerings
7.16.4 Lupin Limited. Antihypertensive Sales and Revenue in Global (2018-2023)
7.16.5 Lupin Limited. Key News & Latest Developments
7.17 Yangtze River Pharmaceutical
7.17.1 Yangtze River Pharmaceutical Company Summary
7.17.2 Yangtze River Pharmaceutical Business Overview
7.17.3 Yangtze River Pharmaceutical Antihypertensive Major Product Offerings
7.17.4 Yangtze River Pharmaceutical Antihypertensive Sales and Revenue in Global (2018-2023)
7.17.5 Yangtze River Pharmaceutical Key News & Latest Developments
7.18 Hengrui Medicine
7.18.1 Hengrui Medicine Company Summary
7.18.2 Hengrui Medicine Business Overview
7.18.3 Hengrui Medicine Antihypertensive Major Product Offerings
7.18.4 Hengrui Medicine Antihypertensive Sales and Revenue in Global (2018-2023)
7.18.5 Hengrui Medicine Key News & Latest Developments
7.19 Qilu Pharmaceutical
7.19.1 Qilu Pharmaceutical Company Summary
7.19.2 Qilu Pharmaceutical Business Overview
7.19.3 Qilu Pharmaceutical Antihypertensive Major Product Offerings
7.19.4 Qilu Pharmaceutical Antihypertensive Sales and Revenue in Global (2018-2023)
7.19.5 Qilu Pharmaceutical Key News & Latest Developments
7.20 HUALON
7.20.1 HUALON Company Summary
7.20.2 HUALON Business Overview
7.20.3 HUALON Antihypertensive Major Product Offerings
7.20.4 HUALON Antihypertensive Sales and Revenue in Global (2018-2023)
7.20.5 HUALON Key News & Latest Developments
7.21 Dawnrays
7.21.1 Dawnrays Company Summary
7.21.2 Dawnrays Business Overview
7.21.3 Dawnrays Antihypertensive Major Product Offerings
7.21.4 Dawnrays Antihypertensive Sales and Revenue in Global (2018-2023)
7.21.5 Dawnrays Key News & Latest Developments
7.22 HISUN Pharmceutical
7.22.1 HISUN Pharmceutical Company Summary
7.22.2 HISUN Pharmceutical Business Overview
7.22.3 HISUN Pharmceutical Antihypertensive Major Product Offerings
7.22.4 HISUN Pharmceutical Antihypertensive Sales and Revenue in Global (2018-2023)
7.22.5 HISUN Pharmceutical Key News & Latest Developments
8 Global Antihypertensive Production Capacity, Analysis
8.1 Global Antihypertensive Production Capacity, 2018-2029
8.2 Antihypertensive Production Capacity of Key Manufacturers in Global Market
8.3 Global Antihypertensive Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Antihypertensive Supply Chain Analysis
10.1 Antihypertensive Industry Value Chain
10.2 Antihypertensive Upstream Market
10.3 Antihypertensive Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Antihypertensive Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(MMG23JU5681 )"降圧剤のグローバル市場展望 2023年-2029年:利尿薬、アンジオテンシン変換酵素(ACE)阻害薬、アンジオテンシン受容体遮断薬(ARB)、カルシウムチャネル遮断薬、ベータ遮断薬、アルファ遮断薬、血管拡張薬&レニン阻害薬" (英文:Antihypertensive Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。